HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Zacks #1 Rank
See how a purely mathematical analysis of earnings estimate revisions returns over 27% per year on average. Click Here to Learn More.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Top 10 Stocks
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive

SSRX: 3sbio Ads - Full Company Report Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Full Company Report |  Estimates |  Brokerage Recommendations |  Comparison to Industry |  Insiders |  Brokerage Reports |  Zacks Equity Research   |  Annual Report
3SBIO ADS (NASD)
SSRX 13.53 N/A (N/A%) Vol.  0 N/A ET
3SBIO INC. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. The Company's protein-based products and product candidates are designed to address markets with medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. The Company's diversified product pipeline includes a number of protein-based therapeutics, including NuPIAO, its second-generation EPIAO product candidate; NuLeusin, its next-generation Inleusin product candidate; TPIAO for the treatment of idiopathic thrombocytopenic purpura, a human papilloma virus vaccine for the prevention of cervical cancer, and an anti-tumor necrosis factor humanized monoclonal antibody product candidate for the treatment of rheumatoid arthritis and other autoimmune diseases.

 General Information
3SBIO INC-ADS
-
-, - -
Phone: -
Fax: -
Web: -
Email: None
 
Industry MED-BIOMED/GENE
Sector: Medical
 
Fiscal Year End December
Last Reported Quarter 09/30/09
Next EPS Date 03/10/2010
 
 Price and Volume Information
Zacks Rank
Yesterday's Close 13.53
52 Week High 13.72
52 Week Low 4.18
Beta 1.70
20 Day Moving Average 99,743.70
Target Price Consensus 14.1
 
 % Price Change
4 Week 12.74
12 Week 26.40
YTD 64.49
 % Price Change Relative to S&P 500
4 Week 11.52
12 Week 19.17
YTD 36.13
 Share Information
Shares Outstanding (millions) 21.51
Market Capitalization (millions) 275.99
Short Ratio 1.82
Last Split Date N/A
 Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio 0.00
Change in Payout Ratio 0.00
Last Dividend Payout / Amount NA / $0.00

 EPS Information
Current Quarter EPS Consensus Estimate 0.07
Current Year EPS Consensus Estimate 0.57
Estimated Long-Term EPS Growth Rate 23.00
Next EPS Report Date 03/10/2010
 Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell) 1.00
30 Days Ago 1.00
60 Days Ago 1.00
90 Days Ago 1.00

 Fundamental Ratios
 P/E
Current FY Estimate: 22.41
Trailing 12 Months: 22.12
PEG Ratio 0.97
 EPS Growth
vs. Previous Year 28.57%
vs. Previous Quarter 0.00%
 Sales Growth
vs. Previous Year 35.08%
vs. Previous Quarter: 13.65%
 Price Ratios
Price/Book 1.89
Price/Cash Flow 23.24
Price / Sales 6.23
 ROE
09/30/09 8.99
06/30/09 8.54
03/31/09 7.83
 ROA
09/30/09 8.63
06/30/09 8.21
03/31/09 7.51
 Current Ratio
09/30/09 20.25
06/30/09 25.78
03/31/09 21.34
 Quick Ratio
09/30/09 19.97
06/30/09 25.49
03/31/09 21.11
 Operating Margin
09/30/09 28.36
06/30/09 28.68
03/31/09 28.28
 Net Margin
09/30/09 26.96
06/30/09 20.22
03/31/09 18.53
 Pre-Tax Margin
09/30/09 26.96
06/30/09 20.22
03/31/09 18.53
 Book Value
09/30/09 6.77
06/30/09 6.58
03/31/09 6.31
 Inventory Turnover
09/30/09 2.54
06/30/09 2.80
03/31/09 2.89
 Debt-to-Equity
09/30/09 -
06/30/09 -
03/31/09 -
 Debt to Capital
09/30/09 -
06/30/09 -
03/31/09 -

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research